Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine
Executive Summary
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia
Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.
Foundation Medicine Seeks "Go-To" Companion Diagnostic Status For Sequencing Test
Foundation says its test service will transition next-generation sequencing from the research bench to routine clinical practice, with the ultimate goal of supplanting the need for individual gene mutation tests to drive oncology drug therapy decisions.